New @TheLancet: Induction therapy with risankizumab for moderate-to-severe #crohnsdisease: a ph 2 trial… https://t.co/oTp7iqZtJ5
New @TheLancet: Induction therapy with risankizumab for moderate-to-severe #crohnsdisease: a ph 2 trial… https://t.co/oTp7iqZtJ5